Combination of Ceftriaxone and Ampicillin for the Treatment of Enterococcal Endocarditis: A Qualitative Systematic Review

Peterson, S; Lau, Tim T Y; Ensom, Mary H H

doi:10.1177/1060028017692357

Cited by 13 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is increasing interest in combining different β-lactams, with and without β-lactam inhibitors, for their additive or synergistic effects against different pathogens. The combination of penicillins and ceftriaxone has been shown to be efficacious against Enterococcus faecalis endocarditis, and the combination of aztreonam with ceftazidime-avibactam has been successfully used to treat infection with metallo-β-lactamase-producing Enterobacteriaceae (35–38). Whether combining ceftazidime with ceftaroline or imipenem based on our promising in vitro susceptibility and time-kill data will prove to be an effective addition to current treatment regimens will require further animal and/or in vitro efficacy studies to further our knowledge.…”

Section: Discussionmentioning

confidence: 99%

Dual β-Lactam Combinations Highly Active against Mycobacterium abscessus Complex In Vitro

Pandey

Chen

Manca

et al. 2019

mBio

View full text Add to dashboard Cite

The emergence of chronic MABC infections among immunocompromised populations and their inherent and acquired resistance to effective antibiotic therapy have created clinical challenges in advancing patients for transplant surgery and treating those with disease. There is an urgent need for new treatment regimens, and the repurposing of existing antibiotics provides a rapid strategy to advance a laboratory finding to patient care. Our recent discoveries that dual β-lactams, specifically the combination of ceftazidime with ceftaroline or ceftazidime with imipenem, have significant in vitro MIC values and kill curve activities and are effective against infected THP-1 human macrophages provide optimism for a dual β-lactam treatment strategy against MABC infections. The unexpected synergistic activities reported in this study create a new path of discovery to repurpose the large family of β-lactam drugs.

show abstract

Section: Discussionmentioning

confidence: 99%

Dual β-Lactam Combinations Highly Active against Mycobacterium abscessus Complex In Vitro

Pandey

Chen

Manca

et al. 2019

mBio

View full text Add to dashboard Cite

show abstract

“…Further studies are needed to evaluate the efficacy and safety of a sequential regimen comprising 7 to 14 days of A-G followed by A-C combination. A prospective study including long-term patient follow-up is still necessary [ 31 , 32 ].…”

Section: Discussionmentioning

confidence: 99%

Impact of Enterococcus faecalis Endocarditis Treatment on Risk of Relapse

Danneels

Hamel

Picard

et al. 2022

Clinical Infectious Diseases

View full text Add to dashboard Cite

Background Enterococcus faecalis infective endocarditis (EFIE) are characterized by a higher frequency of relapses than other infective endocarditis. The role of the treatment on their occurrence remains poorly understood. The aim of this study was to investigate whether the antibiotic regimen could impact the risk of relapse in EFIE. Materials This was a multicenter retrospective study of patients diagnosed with definite EFIE between 2015 and 2019 in 14 French hospitals. The primary endpoint was the occurrence of relapses within the year following endocarditis diagnosis. As death was a competing risk for relapse, Fine & Gray models were used for studying risk factors and impact of treatment. Results Of the 279 patients included, 83 (29.7%) received the amoxicillin-gentamicin (A-G) combination, 114 (40.9%) amoxicillin-ceftriaxone (A-C), 63 (22.6%) A-G and A-C (A-G/A-C) sequentially, 9 (3.2%) amoxicillin (A), and 10 received other treatments. One-year-relapse rate was 9.3% (26 patients). Relapse occurred after a median delay of 107 days from EFIE diagnosis; 6 occurred after 6 months, and 6 were diagnosed by blood cultures in asymptomatic patients. In multivariate analysis, surgery during treatment was a protective factor against one-year relapse and death. The cumulative incidence of relapse one year after endocarditis was 46.2% for patients treated with amoxicillin, 13.4% with A-G, 14.7% with A-C, and 4.3% with A-G/A-C (P≥.05 in multivariate analysis). Conclusion Relapses after treatment of EFIE are frequent, frequently asymptomatic, and may occur more than 6 months after the initial episode.

show abstract

“…Above all, similar success and mortality rates combined with the lower risk of nephrotoxicity and the lack of need for measuring aminoglycoside serum concentrations, place this therapeutic combination as a meaningful and wise treatment option for patients with EFIE regardless of HLAR status. Therefore, patients receiving this therapy should be monitored for leukopenia by assessing complete blood counts weekly after initiation of treatment and for the increased risk of vancomycin-resistant Enterococcus (VRE) gastrointestinal colonization [ 34 , 35 ].…”

Section: Discussionmentioning

confidence: 99%

Ampicillin Plus Ceftriaxone Regimen against Enterococcus faecalis Endocarditis: A Literature Review

Marino

Munafò

Zagami

et al. 2021

JCM

View full text Add to dashboard Cite

Enterococcus faecalis infective endocarditis (EFIE) continues to represent a potentially fatal infectious disease characterized by elevated morbidity and mortality. Despite advances in antimicrobial therapy, changing demographics and the reduced availability of useful antibiotics combined with the dissemination of multi-drug resistant strains, the mortality rate remained unchanged in the last decades. Nowadays, optimizing the antibiotic regimen is still of paramount importance. Historically, aminoglycosides were considered as a cornerstone for treatment even though their use is associated with a high risk of kidney failure. It is against this background that, in recent years, several studies have been carried in order to assess the validity of alternative therapeutic approaches, including combinations of beta-lactams, that, acting synergistically, have yielded useful results in different clinical settings. In this scenario, we searched and critically report clinical studies assessing the efficacy and safety of double beta-lactam therapy in treating EFIE.

show abstract

Combination of Ceftriaxone and Ampicillin for the Treatment of Enterococcal Endocarditis: A Qualitative Systematic Review

Cited by 13 publications

References 22 publications

Dual β-Lactam Combinations Highly Active against Mycobacterium abscessus Complex In Vitro

Dual β-Lactam Combinations Highly Active against Mycobacterium abscessus Complex In Vitro

Impact of Enterococcus faecalis Endocarditis Treatment on Risk of Relapse

Ampicillin Plus Ceftriaxone Regimen against Enterococcus faecalis Endocarditis: A Literature Review

Contact Info

Product

Resources

About